Kymera Therapeutics (KYMR) Income from Continuing Operations (2019 - 2026)

Kymera Therapeutics (KYMR) has 8 years of Income from Continuing Operations data on file, last reported at 494753000.0 in Q1 2026.

• On a quarterly basis, Income from Continuing Operations fell 151.9% year-over-year to 494753000.0 in Q1 2026; TTM through Mar 2026 was 1154028000.0, a 90.29% decrease from a year earlier, with the FY2025 full-year figure at 749889000.0, down 50.63% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 494753000.0, down from 97896000.0 in the prior quarter.
• Over the last five years, Income from Continuing Operations for KYMR reached as high as 38685000.0 in Q4 2022 and fell as low as 494753000.0 in Q1 2026.
• Historically, Income from Continuing Operations has averaged 175463705.88 across 5 years, with a median of 168486000.0 in 2022.
• Across the five-year window, Income from Continuing Operations jumped 65.08% in 2022 and slumped 369.66% in 2023, its largest moves.
• Year by year, Income from Continuing Operations stood at 38685000.0 in 2022, then slumped by 369.66% to 181687000.0 in 2023, then soared by 55.54% to 80771000.0 in 2024, then retreated by 21.2% to 97896000.0 in 2025, then tumbled by 405.39% to 494753000.0 in 2026.
• Per Business Quant data, the three most recent Income from Continuing Operations figures were 494753000.0 in Q1 2026, 97896000.0 in Q4 2025, and 342576000.0 in Q3 2025.